We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Vitamin D Measured in Patients with Diabetic Foot

By LabMedica International staff writers
Posted on 19 Dec 2018
Print article
Image: The Lumipulse G 25-OH Vitamin D is an immunoreaction cartridge for in vitro diagnostic for the quantitative determination of 25-hydroxyvitamin D (25(OH)D) in human serum or plasma to be used in the assessment of Vitamin D sufficiency (Photo courtesy of Fujirebio).
Image: The Lumipulse G 25-OH Vitamin D is an immunoreaction cartridge for in vitro diagnostic for the quantitative determination of 25-hydroxyvitamin D (25(OH)D) in human serum or plasma to be used in the assessment of Vitamin D sufficiency (Photo courtesy of Fujirebio).
Peripheral artery disease (PAD) is the underlying predisposing factor in the etiology of the majority of diabetic feet. Vitamin D plays a role in calcium and bone metabolism and it is known to be an important immune modulator agent.

Osteoprotegerin (OPG) is a glycoprotein, which is a member of the tumor necrosis factor (TNF) family. Osteoprotegerin was first found in the bones and it acts as a strong anti-resorptive factor. The effect of osteoprotegerins is demonstrated by binding or neutralizing the receptor activator nuclear factor kappa B ligand (RANKL).

Medical scientists at the Bağcılar Training and Research Hospital (Istanbul, Turkey) conducted a prospective study on 105 patients including 58 patients with diabetic foot (42 males, 16 females; mean age 63.6 years; range, 31 to 90 years), who applied to the hospital between June 2014 and May 2015, and 47 newly diagnosed type 2 diabetes mellitus (DM) patients (27 males, 20 females; mean age 51.4 years; range, 29 to 85 years) (control group).

Serum concentration of 25-hydroxyvitamin D (25(OH)D) was determined by using electrochemiluminescence immunoassay utilized in fasting patients’ morning blood samples. Serum concentration of OPG was determined by enzyme-linked immunosorbent assay (ELISA) using the same blood samples. For OPG ELISA eBioscience kit, reference values for normal serum samples were 5-100 pg/mL.

The team found that osteoprotegerin levels in diabetic foot group were significantly higher than the control group. The 25(OH)D levels in diabetic foot group were significantly lower than the control group. There were positive correlations between OPG levels and C-reactive protein (CRP) and creatinine levels in patients with diabetic foot. The glycated hemoglobin (HbA1c) value did not differ significantly between the diabetic foot and control groups.

The authors concluded that elevated levels of OPG in patients with diabetic foot may display the severity of the clinical status due to its positive correlation with CRP and creatinine. They detected severe 25(OH)D deficiency in the majority of diabetic foot patients. Vitamin D supplementation may be required in diabetic foot patients to prevent unfavorable immunologic alterations. The study was published in the December 2018 in the journal Joint Diseases and Related Surgery.

Related Links:
Bağcılar Training and Research Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more